Janssen Pharmaceutical Inc.
1125 Trenton-Harbourton Road
Titusville
New Jersey
08560
United States
Tel: 609-730-2000
120 articles with Janssen Pharmaceutical Inc.
-
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
-
Johnson & Johnson’s Janssen division has decided to end its trials of atabacestat, a BACE inhibitor, for Alzheimer’s disease.
-
Janssen Announces DARZALEX® (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible
5/8/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) in combination with VELCADE® (bortezomib).
-
GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development
5/8/2018
GenomeDx Biosciences announced a research collaboration with Janssen Pharmaceuticals.
-
Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
-
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
-
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
-
Janssen Strikes Deal to Acquire BeneVir and its Oncolytic Virus Platform in Deal Worth Up to $1 B...
5/2/2018
Shares of HC2 Holdings, Inc. skyrocketed more than 51 percent in premarket trading today after Janssen Biotech Inc announced it was acquiring Rockville, Maryland-based BeneVir Biopharm, Inc., a subsidiary of HC2 in a deal that could be worth more than $1 billion. -
At the end of 2016, there were an estimated 36.7 million people living with HIV across the globe. With a large and growing patient population, the market for HIV treatments is expected to grow to $22.5 billion by 2025.
-
Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
4/27/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the results of a real-world study showing that adults with type 2 diabetes initiated on INVOKANA®.
-
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
-
Fujirebio Enters into Agreement with Janssen Pharmaceuticals to Develop and Commercialize AMYLOID β 42/40 RATIO Assay
4/26/2018
The Lumipulse® series is intended to help identify patients who may benefit from treatment with Janssen’s new investigational oral BACE inhibitor, atabecestat.
-
Public health officials and scientists have had concerns about how long Ebola vaccines’ protection lasts. A new study shows that one of those vaccines confers at least two years of protection.
-
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
-
Newly Published Phase 2 Study Found Esketamine Demonstrated Significantly Rapid Improvements in Depressive Symptoms and Suicidality
4/16/2018
If approved by the FDA, esketamine nasal spray would be the first medication for treatment of patients with major depressive disorder at imminent risk for suicide.
-
INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
4/12/2018
New analysis further supports the potential renal protective effects of INVOKANA®
-
Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC).
-
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer
3/15/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for erdafitinib in the treatment of urothelial cancer.
-
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Heart Failure-Related Outcomes in Type 2 Diabetes Patients at Risk for or With a History of Cardiovascular Disease
3/11/2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new analysis showing that INVOKANA® (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk.